Blog

Categories

Eagle Biosciences Announces Distribution Agreement with Genetic Analysis

by Eagle Biosciences

Eagle Biosciences Announces Agreement with Genetic Analysis

Eagle Biosciences Announces Agreement with
Genetic Analysis AS for Distribution in North America

Eagle Biosciences, Inc., a North American distributor of assay kits and antibodies, recently announced a distribution agreement with Genetic Analysis AS, a Norwegian molecular diagnostics company. The focus of the collaboration is on the unique, patented GA-map® Dysbiosis Test which detects and characterizes imbalance in the gut microbiota (dysbiosis) in human fecal samples. Additionally, Genetic Analysis has developed a fecal COVID-19 test that is performed on the same GA-map platform and is an important research tool in the analysis of an individual’s COVID-19 status.

Genetic Analysis (GA) is a molecular diagnostics company with a core focus of providing innovative tools for studying the human microbiome. GA has developed and launched the GA-map platform for routine gut microbiome research and analysis. The first test on this groundbreaking platform is the GA-map Dysbiosis Test. The Dysbiosis Test is the first documented test to identify and characterize the gut microbiota composition. The GA-map Test platform is not based on sequencing but is a targeted probe-based assay. The precise and targeted approach makes it an easy plug and play platform as long as the targets are identified. GA’s vision is to become the company that standardizes gut microbiota testing worldwide.

“We are looking forward to working with Genetic Analysis and the opportunity to bring their products to labs in the US and Canada.”, states Eagle Biosciences President Dan Keefe. “Genetic Analysis has been a pioneer in the microbiota industry and has over ten years of experience in the field. We are especially excited about their GA-map® Dysbiosis Test because it is the first standardized, off-the-shelf biome mapping kit and can be run in any PCR lab.”

If you have any questions about the GA-map® test platform or any of Eagle Biosciences products, please contact us here.

About Genetic Analysis AS

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s mission is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering.

For more information about Genetic Analysis, click here.

About Eagle Biosciences, Inc.

Since 2010, Eagle Biosciences has been providing the highest quality and best value immunoassays, antibodies, and proteins available on the market. There are many suppliers of ELISAs and other assays and hundreds of thousands of products to choose from, but EagleBio only offers products that deliver the maximum level of performance and provide reliable and trusted results.

For more information about Eagle Biosciences, Inc., click here.

Categories

Biomarker Spotlight: Sclerostin

by Eagle Biosciences

Sclerostin Biomarker Spotlight
Sclerostin is a secreted glycoprotein that functions as a potent inhibitor of Wnt signaling. It acts by binding to the Wnt-coreceptor LRP5/6 thus inhibiting bone formation by regulating osteoblast function and promoting osteoblast apoptosis. Sclerostin is primarily produced by osteocytes. It inhibits the canonical Wnt pathway and thereby osteoblasts. It also stimulates RANKL release by the osteocytes and thereby osteoclast recruitment. Inhibition of sclerostin causes stimulation of bone formation and inhibition of resorption. Read more about sclerostin’s role in bone remodeling here.

Sclerostin levels are altered in response to hormonal stimuli or due to pathophysiological conditions. The concentrations are increased in disorders such as hypoparathyroidism, Paget’s disease, multiple myeloma and in cancer induced bone diseases. Mutations in the SOST gene can cause sclerosteosis and van Buchem disease which are bone dysplasia disorders characterized by progressive skeletal overgrowth. Sclerostin levels are decreased in primary hyperparathyroidism, as well as by the mechanical stimulation of bone.

A mini-review was published in the The Journal of Clinical Endocrinology & Metabolism regarding the effect of sclerostin inhibition on the cardiovascular safety of patients. Read the full text here.

Eagle Biosciences offers a sensitive and reliable assay for the detection of sclerostin in serum and plasma samples.

Advantages of the Sclerostin ELISA Assay Kit

    • High Quality – rigorously validated according to ICH/FDA/EMEA guidelines
    • Low Sample Volume – only 20ul of sample per well
    • Easy – ready to use protocol, standards and controls included

Related Products

Osteoprotegerin ELISA Assay Kit
Free Soluble RANKL ELISA Assay Kit
FGF23 C-Terminal ELISA Assay Kit

If you are looking for any other specific related products, or have any questions about our offerings contact us here.

Categories

New Product: Human Il-6 High Sensitive ELISA Assay Kit

by Eagle Biosciences

IL-6 High Sensitive ELISA Assay Kit New Product

Eagle Biosciences is excited to announce the Human IL-6 High Sensitive ELISA Assay Kit from Biomedica! This powerful kit offers a wide dynamic range with extraordinary sensitivity. It provides superior performance and reliability for all your researching needs.

About Interleukin-6 (IL-6)

IL-6 is a pleiotropic cytokine that plays a crucial role in regulating the acute phase response, inflammation, hematopoiesis, glucose metabolism, bone metabolism, and cancer progression. IL-6 is an early marker of acute inflammation. In patients with COVID-19, IL-6 levels are significantly elevated and associated with adverse clinical outcomes. Therefore, serum IL-6 is an important biomarker for severity of COVID-19 and has great potential for guiding treatment of the disease.

IL-6 can reliably be measured by ELISA (cat.no. BI-IL6) in human serum, plasma and urine samples with Biomedica’s fully validated assay kit. The kit is highly sensitive and offers a wide dynamic range. The kit incorporates ready to use standards and controls.

Features & Benefits of the Human IL-6 High Sensitive ELISA Assay Kit

√ EASY ready to use calibrators & controls included
√ High SENSITIVITY measurable values in serum and plasma
√ Full validation package – the assay is optimized for clinical samples
√ HIGH QUALITY GUARANTEED

Related publications:

Interleukin-6 in Covid-19: A systematic review and meta-analysis. Coomes EA, Haghbayan H. Rev Med Virol. 2020 Nov;30(6):1-9. Full text.

Assessing the importance of interleukin-6 in COVID-19. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Lancet Respir Med. 2021 Feb;9(2):e13. Full text.

If you have any questions about the Human Il-6 High Sensitive ELISA Assay Kit or any of our other offerings, contact us here.

Categories

RANKL and RANK Biomarker Spotlight

by Eagle Biosciences

RANKL and RANK Biomarker Spotlight

Receptor activator of nuclear factor kappa B ligand, RANKL, and its specific receptor RANK, are members of the tumor necrosis factor (TNF) family and are the main stimulatory factor for the formation of mature osteoclasts and are essential for their survival. The major source of RANKL are osteocytes, former osteoblasts that become embedded within the mineralized bone matrix. RANKL and its specific receptor RANK are not only key regulators of bone remodeling but also play an essential role in immunobiology, e.g. lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, bone metastasis in cancer and sex-hormone, progestin-driven breast cancer, thermoregulation, and finally in the development of type 2 diabetes mellitus.

A recent study has uncovered a new role for RANKL and RANK in bone remodeling. Researchers have found that extracellular vesicles containing RANKL and RANK may have an important role in the long range signaling for bone remodeling. These signaling molecules have the potential to be targeted for therapeutics and also used diagnostically.

Click here to learn more.

Holliday LS, Patel SS, Rody WJ. RANKL and RANK in Extracellular Vesicles: Surprising New Players in Bone Remodeling. Extracell Vesicles Circ Nucleic Acids. 2021; 2:18-28.

Related Products
Free Soluble RANKL ELISA Assay Kit
iLite® RANKL Assay Ready Cells
Osteoprotegerin ELISA Assay Kit
Sclerostin ELISA Assay Kit

Categories

COVID-19 ELISA Highlighted in Recent Study

by Eagle Biosciences

COVID-19 ELISA

Eagle Biosciences’ COVID-19 IgM and IgG ELISA Assay Kits were recently highlighted in a study. This study evaluated the different tools that have become available for COVID testing and research.

Abstract

Recent severe acute respiratory syndrome 2 (SARS-CoV-2) known as COVID-19, presents a deadly challenge to the global healthcare system of developing and developed countries, exposing the limitations of health facilities preparedness for emerging infectious disease pandemic. Opportune detection, confinement, and early treatment of infected cases present the first step in combating COVID-19. In this review, we elaborate on various COVID-19 diagnostic tools that are available or under investigation. Consequently, cell culture, followed by an indirect fluorescent antibody, is one of the most accurate methods for detecting SARS-CoV-2 infection. However, restrictions imposed by the regulatory authorities prevented its general use and implementation. Diagnosis via radiologic imaging and reverse transcriptase PCR assay is frequently employed, considered as standard procedures, whereas isothermal amplification methods are currently on the verge of clinical introduction. Notably, techniques such as CRISPR-Cas and microfluidics have added new dimensions to the SARS-CoV-2 diagnosis. Furthermore, commonly used immunoassays such as enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay (LFIA), neutralization assay, and the chemiluminescent assay can also be used for early detection and surveillance of SARS-CoV-2 infection. Finally, advancement in the next generation sequencing (NGS) and metagenomic analysis are smoothing the viral detection further in this global challenge.

To read more click here.

Oishee MJ, Ali T, Jahan N, et al. COVID-19 Pandemic: Review of Contemporary and Forthcoming Detection Tools. Infect Drug Resist. 2021;14:1049-1082. Published 2021 Mar 17. doi:10.2147/IDR.S289629

Related Products
Coronavirus COVID-19 IgM ELISA Assay Kit
Coronavirus COVID-19 IgG ELISA Assay Kit
COVID-19 Nucleocapsid IgG Quantitative ELISA Assay Kit
COVID-19 S-Protein Specific IgG Quantitative ELISA Assay Kit
COVID-19 Neutralizing Antibody Quantitative ELISA Assay Kit

Categories

Osteoprotegerin Biomarker Spotlight

by Eagle Biosciences

Osteoprotegerin Biomarker Spotlight

Osteoprotegerin (ORG) is a secreted protein that affects bone turnover and is implicated in heart and kidney disease. It is a glycoprotein of the TNF receptor superfamily 11b (gene name TNFRSF11B). OPG is synthesized as a monomer of 380 amino acids and is assembled as a homodimer within the cell and then secreted mainly as a disulfide-linked homodimer into the extracellular compartment. OPG is produced by many different tissues and cell types including osteoblasts. OPG is a negative regulator of bone resorption by acting as decoy receptor for RANKL, thus neutralizing its function in osteoclastogenesis. This glycoprotein is also involved in the regulation of vascular calcification. A recent study identifies OPG as an independent risk factor for all-cause mortality in patients after kidney transplantation. 982 prevalent kidney transplant (KT) recipients were followed up for all-cause mortality for 6 years. The researchers observed that each 1 pmol/L higher-serum OPG level was associated with a 49% higher risk of mortality.

Association between serum osteoprotegerin level and mortality in kidney transplant recipients. Gupta V et al., 2021. Transpl Int 19. doi: 10.1111/tri.13847. Epub ahead of print. PMID: 33606319.

Osteoprotegerin Related Products

Osteoprotegerin ELISA Assay Kit
Sclerostin ELISA Assay Kit
Periostin ELISA Assay Kit

Categories

DHEA ELISA Used in a Recent Study

by Eagle Biosciences

DHEA ELISA Publication

Evidence for fasting induced extra-adrenal steroidogenesis in the male brown anole, Anolis sagrei

The Eagle Biosciences DHEA ELISA was used in a recent study testing if fasting could induce adrenal tissues to produce glucocorticoids (GCs) and dehydroepiandrosterone (DHEA) to coordinate different physiological processes.

Abstract

Glucocorticoids (GCs) and dehydroepiandrosterone (DHEA) are steroids secreted by the adrenal glands into circulation to effect distant target tissues and coordinate physiological processes. This classic systemic view of steroids has been challenged by evidence that other tissues can independently synthesize their own steroids. Little is known however regarding circumstances that can promote this extra-adrenal steroidogenesis. Here we tested if fasting can induce tissues to increase GC and DHEA synthesis in the brown anole lizard Anolis sagrei. Lizards fasted for eight days lost body mass and increased fatty acid oxidation. Fasting also increased plasma concentrations of DHEA and corticosterone, but not cortisol. Corticosterone concentration within the adrenals, heart, intestines, lungs and liver exceeded that in plasma, with the latter two increasing with fasting. Levels of DHEA in the adrenals and heart were higher than in plasma, but no significant effect of fasting was observed, expect for a noticeable increase in intestinal DHEA. Two steroidogenic genes, the steroidogenic acute regulatory (Star) protein and Cyp17a1, a cytochrome P450 enzyme, were expressed in several tissues including the liver, lungs and intestines, which were increased with fasting. Continued research should aim to test for expression of additional enzymes further along the steroidogenic pathway. Nonetheless these data document potential extra-adrenal steroidogenesis as a possible mechanism for coping with energy shortages, although much work remains to be done to determine the specific roles of locally synthesized steroids in each tissue.

To learn more and read the full publication, click here.

Related Products:

DHEA ELISA Assay Kit
DHEA-S ELISA Assay  Kit

Categories

Big Endothelin-1 Biomarker Spotlight

by Eagle Biosciences

Big Endothelin-1 Biomarker Spotlight

Big Endothelin-1 (Big ET-1) is a protein that is mainly produced by vascular endothelial and smooth muscle cells and cardiomyocytes. Big ET-1 is a precursor to Endothelin (ET), the most potent vasoconstrictor known today. The half life of ET is less than one minute, whereas Big ET-1 is cleared more slowly. Big ET-1 can therefore be determined more easily, and has since been identified as a risk factor for a poor prognosis in patients with atrial fibrillation or coronary artery disease. A current study has shown that plasma concentrations of Big ET-1 is a valuable tool for risk stratification in patients with left ventricular non-compaction cardiomyopathy (LVNC). Other studies have also recognized the effectiveness of Big ET-1 as a predictor for numerous cardiovascular diseases.

Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy. Fan P, et al. Heart 2020;0:1–6. doi:10.1136/heartjnl-2020-317059

Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients. Li XY et al., 2020. J Geriatr Cardiol 28;17(7):427-433.

Plasma big endothelin-1 predicts new-onset atrial fibrillation after surgical septal myectomy in patients with hypertrophic cardiomyopathy. Song C et al., 2019. BMC Cardiovasc Disord 22;19(1):122.

Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy. Wang Y et al., 2017. Int J Cardiol 15;243:283-289.

Related Products:

Big Endothelin-1 ELISA Assay Kit.
NT-proANP ELISA Assay Kit
NT-proCNP ELISA Assay Kit
NT-proBNP ELISA
BNP Fragment ELISA Assay Kit

If you have any questions regarding our Big Endothelin-1 ELISA Assay Kit or any other kits in the Cardiovascular Assay line, contact us here.

Categories

EagleBio Highlights ELISpot Kits

by Eagle Biosciences

ELISpot Kits

Eagle Biosciences proudly offers a broad range of products in our extensive catalog. In addition to the well known ELISA format, we offer several assay kits in a enzyme-linked immunospot (ELISpot) assay format.

ELISA vs. ELISpot

ELISAs use antibodies to detect the presence and concentration of a protein in a liquid sample. In the most common form, antigens are applied to a stable surface (usually a microtiter plate). Then the corresponding antibody, linked with an enzyme, is added to form a complex. Finally, the enzyme’s substrate is added, which produces a measurable reaction, usually in the form of a color change.

ELISpots also utilize antibody-enzyme reactions. However, instead of measuring the concentration of protein in a sample, they measure the number of cells secreting the cytokine of interest in a sample. Antigens are applied to the plate surface, and when samples are added, cells settle on the bottom of the wells. The cytokines secreted by the cells are captured by the surrounding antigens. After the appropriate incubation time, the cells are removed and the secreted cytokine is detected using a detection antibody linked with an enzyme. The enzyme’s substrate is added, producing a reaction. The end result is visible spots on the on the surface of the plate. Each spot corresponds to an individual cell that was secreting the target protein.

The information provided by ELISpot kits is applicable to various fields of study including: transplantation, vaccine development, T-cell regulation analysis, autoimmune disease, cancer, allergy, and viral infections. These kits are highly sensitive and easy to use.

ELISpot Kit Procedure

Our available kits:

IFN gamma ELISpot Assay Kit

Mouse IFN gamma ELISpot Assay Kit

Rat IFN gamma ELISpot Assay Kit

TNF alpha ELISpot Assay Kit

Rat TNF alpha ELISpot Assay Kit

Contact us if you are looking for a specific ELISpot or if you have questions about any of our products.

Categories

Calprotectin ELISA Highlighted in a Recent Study

by Eagle Biosciences

Calprotectin ELISA

Does Human Milk Fortifier Affect Intestinal Inflammation in Preterm Infants?

Eagle Biosciences’ Calprotectin ELISA Assay Kit was used in a recent study dealing with inflammation of preterm infants in response to human milk fortifier. The Calprotectin ELISA Assay is part of our line of Gastrointestinal Assays which is a line of highly sensitive and specific kits used to detect the concentration of a variety of samples in serum, plasma, tissue, urine, and saliva.

Abstract

Background: Fecal calprotectin, a recognized marker of intestinal inflammation, is derived from neutrophil migration to a site of inflammation. Introduction of bovine-based human milk fortifier containing intact protein in preterm infants is associated with an increase in fecal calprotectin suggestive of intestinal inflammation. Newer fortifiers contain protein hydrolysates in place of intact protein.

Objective: To measure fecal calprotectin in human milk-fed preterm infants before and after human milk fortification using a fortifier containing hydrolyzed protein.

Methods: Serial stool samples were collected from 24 infants beginning at the first week to 60 days postnatal age. To compare the effect of human milk fortification, samples collected before and after fortification were compared. Infant demographics, diet, postnatal morbidities, and maternal characteristics were recorded.

Results: A total of 401 stool samples were collected from 24 study infants who had a birth weight of 993 ± 277 g (mean ± standard deviation), gestational age 27.5 ± 2.8 weeks, and fortifier initiation at 14 days. Median fecal calprotectin before and after fortification were similar. Calprotectin levels were not correlated with birth weight or gestational age but were inversely correlated with postnatal age (p = 0.005), use of fortifier (p < 0.001), receipt of antibiotics antenatally (p = 0.007) and postnatally (p = 0.008). After adjusting for postnatal age, calprotectin levels were significantly lower following receipt of fortifier (p < 0.001) and postnatal antibiotics (p < 0.001).

Conclusions: The feeding of protein hydrolysate-containing human milk fortifiers does not appear to be associated with increases in a marker of intestinal inflammation.

Click here for the full text.

Related Products

NGAL (Stool) ELISA Assay Kit
S100A8/A9 (MRP8/14, Calprotectin, Mouse/Rat) ELISA Kit
Stool Sample Collection Kit